Lercapin (Lercanidipine Hydrochloride)

Lercapin is a dihydropyridine calcium‑channel blocker used to manage elevated blood pressure.

• Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension.
• Secondary hypertension: helps control blood pressure when it is caused by an underlying condition.
• Hypertensive emergencies (under specialist supervision): may be incorporated into a regimen to lower dangerously high blood pressure.

• Lercanidipine blocks L‑type calcium channels in vascular smooth‑muscle cells, decreasing calcium influx. This inhibition leads to relaxation of arterial smooth muscle, vasodilation, and a subsequent reduction in peripheral vascular resistance, which lowers systemic blood pressure.

Lercapin may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or feet.
• Dizziness: especially when standing quickly.
• Tachycardia: increased heart rate.
• Nausea: occasional stomach upset.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Myocardial infarction: rare occurrence of heart attack.
• Angioedema: swelling of face, lips, or throat.
• Elevated liver enzymes: indication of hepatic stress.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Cardiac conduction disturbances: such as heart block.

Before initiating therapy with Lercapin, certain safety considerations are recommended.

• Monitor blood pressure: check regularly after starting treatment.
• Assess cardiovascular status: use caution in patients with heart failure.
• Evaluate renal function: adjust use if severe impairment is present.
• Review concomitant medications: avoid known major interactions.
• Pregnancy and lactation: prescribe only if clearly needed after risk assessment.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Lercapin can interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• CYP3A4 inhibitors: may increase plasma concentrations of lercanidipine.
• Strong CYP3A4 inducers: may reduce therapeutic effect.
• Other antihypertensives: risk of excessive hypotension.
• Grapefruit juice: can raise drug levels.
• Lithium: may elevate lithium concentrations.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood‑pressure lowering effect.
• Diuretics: may enhance antihypertensive response.
• Antiplatelet agents: monitor for increased bleeding risk.
• NSAIDs: can blunt antihypertensive efficacy.
• Alcohol: may increase dizziness and hypotension.